Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2018 | Research

Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar

Authors: Anna Roberto, Silvia Radrezza, Paola Mosconi

Published in: Journal of Ovarian Research | Issue 1/2018

Abstract

Background

In recent years the question of the lack of transparency in clinical research has been debated by clinicians, researchers, citizens and their representatives, authors and publishers. This is particularly important for infrequent cancers such as ovarian cancer, where treatment still gives disappointing results in the majority of cases. Our aim was to assess the availability to the public of results in ClinicalTrials.gov, and the frequency of non-publication of results in ClinicalTrials.gov and in PubMed, Embase and Google Scholar. We collected all trials on ovarian cancer identified as “completed status” in the ClinicalTrials.gov registry on 17 January 2017. We checked the availability of the results in ClinicalTrials.gov and systematically identified published manuscripts on results.

Results

Out of 2725 trials on ovarian cancer identified, 752 were classified as “completed status”. In those closed between 2008 and 2015, excluding phase I, the frequency of results in ClinicalTrials.gov was 35%. Of the 752 completed studies the frequency of published results in PubMed, Embase or Google Scholar ranged from 57.9% to 69.7% in the last years.

Conclusions

These findings show a lack of transparency and credibility of research. Citizens or patients’ representatives, with the medical community, should continuously support initiatives to improve the publication and dissemination of clinical study results.

Liberati A. An unfinished trip through uncertainties. BMJ. 2004;328(7438):531.

Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ. 2013;347:f6104.CrossRefPubMedPubMedCentral

Lomas A. I’m a patient: show me the trial data. BMJ. 2013;346:f2336.CrossRefPubMed

Chalmers IGP. All trials must be registered and the results published. BMJ. 2013;346:f105. https://doi.org/10.1136/bmj.f105.CrossRefPubMed

Groves T, Godlee F. The European medicines Agency’s plans for sharing data from clinical trials. BMJ. 2013;346:f2961.CrossRefPubMed

Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ. 2013;346:f2865.CrossRefPubMedPubMedCentral

http://www.equator-network.org/wp-content/uploads/2013/08/4614_3rd-EQUATOR-Annual-Lecture-Hazel-Thornton.pdf. Accessed 4 Apr 2018.

Kmietowicz Z. Transparency campaigners welcome new rules for clinical trials in Europe. BMJ. 2014;348:g2579.CrossRefPubMed

Food and Drug Administration Modernization Act of 1997. US public law 105-15. (1997, Nov 21); 21 USC 301.

10.

Zarin DA, Tse T. Medicine. Moving toward transparency of clinical trials. Science. 2008;319:1340–2.CrossRefPubMedPubMedCentral

11.

De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal. N Engl J Med. 2004;351:1250–1.CrossRefPubMed

12.

Food and Drug Administration Amendments Act of 2007. US public law 110-85. (2007, sept 27); 21 USC 301.

13.

ClinicalTrials.gov. FDAAA 801 requirements. National Institutes of Health. https://clinicaltrials.gov/ct2/manage-recs/fdaaa. Accessed 4 Apr 2018.

14.

Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest. 2009;136:295–303.CrossRefPubMedPubMedCentral

15.

Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in — the final rule. N Engl J Med. 2016;375(20):1998–2004.CrossRefPubMedPubMedCentral

16.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-403. https://doi.org/10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.

17.

Data element definitions http://prsinfo.clinicaltrials.gov/definitions.html. Accessed 4 Apr 2018.

18.

Basic results https://prsinfo.clinicaltrials.gov/ResultsDetailedReviewItems.pdf. Accessed 4 Apr 2018.

19.

Guo SW, Evers JL. Lack of transparency of clinical trials on endometriosis. Obstet Gynecol. 2013;121:1281–90.CrossRefPubMed

20.

Huser V, Cimino JJ. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS One. 2013;8:e68409.CrossRefPubMedPubMedCentral

21.

Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014;160:477–83.CrossRefPubMedPubMedCentral

22.

Mayor S. Half of drug trials with results on ClinicalTrials.gov are not published in journals. BMJ. 2013;347:f7219.CrossRefPubMed

23.

Mosconi P, Roberto A. Working together to improve the credibility and transparency of clinical research. BMJ. 2013;347:f7590.CrossRefPubMed

24.

Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374:86–9.CrossRefPubMed

25.

Pranić S, Marušić A. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles. J Clin Epidemiol. 2016;70(Supplement C):26–37.CrossRefPubMed

26.

Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet. 2011;378:1777–8.CrossRefPubMed

27.

Groves T. Big strides in Europe towards clinical trial transparency. BMJ. 2014;349:g6276.CrossRefPubMed

28.

Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med. 2017;376(4):383–91.CrossRefPubMedPubMedCentral

29.

Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.

30.

E3_Guideline.pdf [Internet]. [cited 2018 Mar 14]. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf. Accessed 4 Apr 2018.

31.

Pansieri C, Pandolfini C, Bonati M. The evolution in registration of clinical trials: a chronicle of the historical calls and current initiatives promoting transparency. Eur J Clin Pharmacol. 2015;71(10):1159–64.CrossRefPubMed

32.

Gazzetta Ufficiale dell’Unione Europea L158 [Internet]. [cited 2017 Dec 14]. Available from: http://eur-lex.europa.eu/legal-content/IT/TXT/PDF/?uri=OJ:L:2014:158:FULL&from=IT. Accessed 4 Apr 2018.

33.

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

34.

Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in clinicaltrials.gov and high-impact journals. JAMA. 2014;311(10):1063–5.CrossRefPubMedPubMedCentral

35.

Smith SM, Wang AT, Pereira A, Chang RD, McKeown A, Greene K, et al. Discrepancies between registered and published primary outcome specifications in analgesic trials: ACTTION systematic review and recommendations. Pain. 2013;154(12):2769–74.CrossRefPubMed

36.

Dwan K, Altman DG, Clarke M, Gamble C, Higgins JPT, Sterne JAC, et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med. 2014;11(6):e1001666.CrossRefPubMedPubMedCentral

Title: Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar
Authors: Anna Roberto
Silvia Radrezza
Paola Mosconi
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-018-0404-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar

Abstract

Background

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Cross-linked hyaluronan gel inhibits the growth and metastasis of ovarian carcinoma

Precise preoperative diagnosis of struma ovarii with pseudo-Meigs’ syndrome mimicking ovarian cancer with the combination of 131I scintigraphy and 18F–FDG PET: case report and review of the literature

A case of ovarian clear cell carcinoma arising from ovarian mature cystic teratoma

With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization

Ovarian teratoma in children: a plea for collaborative clinical study

Adipokine RBP4 drives ovarian cancer cell migration